- Once valued at $10B, bluebird bio sold to private equity firms for $29M FiercePharma
- Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker CNBC
- bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital Business Wire
- What’s Going On With Gene Therapy Company Bluebird Bio Stock Today? Yahoo Finance
- Bluebird Bio to Be Acquired by Carlyle Group, SK Capital The Wall Street Journal
Once valued at $10B, bluebird bio sold to private equity firms for $29M – FiercePharma
